Citi analyst Geof Meacham lowered the firm’s price target on Avidity Biosciences (RNA) to $72 from $75 and keeps a Buy rating on the shares after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback